Ziconotide

Generic Name
Ziconotide
Brand Names
Prialt
Drug Type
Small Molecule
Chemical Formula
C102H172N36O32S7
CAS Number
107452-89-1
Unique Ingredient Identifier
7I64C51O16
Background

Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements. Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.

Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.

Indication

用于需要鞘内治疗且对其他镇痛治疗(如应用全身性镇痛药或鞘内注射吗啡等)不耐受或疗效差的严重慢性疼痛患者。

Associated Conditions
Severe, Chronic Pain
Associated Therapies
-

Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy

First Posted Date
2013-11-25
Last Posted Date
2018-09-18
Lead Sponsor
Aaron Boster
Registration Number
NCT01992562
Locations
🇺🇸

The Ohio State University Department of Neurology, Columbus, Ohio, United States

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

First Posted Date
2013-06-27
Last Posted Date
2017-03-16
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
93
Registration Number
NCT01888120
Locations
🇺🇸

Clearwater Pain Management, Clearwater, Florida, United States

🇺🇸

Integrated Pain Solutions, Columbus, Ohio, United States

🇺🇸

Desert Pain Institute, Mesa, Arizona, United States

and more 39 locations

Intrathecal Bolus Doses of Ziconotide

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-06-15
Last Posted Date
2014-12-30
Lead Sponsor
University Hospital, Linkoeping
Target Recruit Count
26
Registration Number
NCT01373983
Locations
🇸🇪

Pain and Rehabilitation Centre, University Hospital, Linköping, Sweden

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2009-10-16
Last Posted Date
2023-03-24
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
16
Registration Number
NCT00996983
Locations
🇮🇹

Istituto Nazionale dei Tumori , Unita Terapia Antalgica, Napoli, Italy

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Phase 3
Completed
Conditions
First Posted Date
2004-02-04
Last Posted Date
2015-12-14
Lead Sponsor
Elan Pharmaceuticals
Target Recruit Count
300
Registration Number
NCT00076544
Locations
🇺🇸

The University of Chicago, Dept. of Surgery, Section of Neurosurgery, Chicago, Illinois, United States

🇺🇸

The Center for Pain Relief, Charleston, West Virginia, United States

🇺🇸

Alabama Pain Center, Huntsville, Alabama, United States

and more 60 locations

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Neurex
Target Recruit Count
100
Registration Number
NCT00002160
Locations
🇺🇸

Emory Univ Hosp, Atlanta, Georgia, United States

🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States

and more 41 locations
© Copyright 2024. All Rights Reserved by MedPath